Linnet Zia

Early in life, Linnet saw firsthand how a clinical trial can radically extend and improve a cancer patient’s life. She became deeply interested in how targeted therapies can play a crucial role in optimizing treatment for oncology patients. Working in drug development, Linnet combines her desire to improve patients’ lives with her passion for turning data into actionable insights.

Linnet joined Revolution Medicines in March 2019 and has played a key leadership role in the evolution of the Finance department. She has over 15 years of finance, accounting, and commercial operations experience and has worked at oncology focused biotech companies for over 12 years. Prior to RevMed, Linnet worked at Aduro Biotech and Onyx Pharmaceuticals (now Amgen), holding various roles in both Finance and Commercial organizations, including supporting the launch and commercialization of KYPROLIS® (carfilzomib) and BLINCYTO® (blinatumomab). She started her professional career in the life sciences practice at Ernst & Young.

Linnet received her bachelor’s degree from UCLA in Economics with an emphasis in Accounting and holds an active CPA license.